Current evidence on the safety of micropressure therapy for refractory Ménière's disease is inadequate in quantity. There is some evidence of efficacy, but it is based on limited numbers of patients. Therefore, this procedure should only be used with special arrangements for clinical governance, consent and audit or research.
Clinicians wishing to undertake micropressure therapy for refractory Ménière's disease should take the following actions.
Inform the clinical governance leads in their Trusts.
Ensure that patients understand the uncertainty about the procedure's efficacy and provide them with clear written information. In addition, the use of NICE's information for the public is recommended.
Audit and review clinical outcomes of all patients having micropressure therapy for refractory Ménière's disease (see section 3.1).
NICE encourages further research into micropressure therapy for refractory Ménière's disease. Research studies should report long-term outcomes, in particular the need for subsequent surgical treatment.